Pat Roberts actually said...
As part of such scrutiny, policymakers should examine whether brand drug manufacturers may abuse their market power to delay or impede generic entry.
Context
Roberts emphasizes the need to scrutinize brand drug manufacturers' market power.
10/16/2017